Full text is available at the source.
Abstract
Recent evidence suggests that glucagon-like peptide-1 receptor (GLP-1R) agonists may reduce drug-seeking behaviors related to psychostimulants and nicotine.
- Psychostimulant use disorder and nicotine use disorder affect tens of millions globally.
- No clinically-approved medications currently exist for treating psychostimulant use disorder.
- Existing treatments for nicotine use disorder show limited long-term effectiveness.
- GLP-1R agonists may be repurposed to target behaviors associated with both disorders.
- The review discusses neural mechanisms and central GLP-1 circuits involved in drug-seeking behaviors.
Simplified